What it's for (Indications)
- Nifedipine is primarily indicated for the management of chronic stable angina (also known as effort-associated angina) and vasospastic angina (Prinzmetal's or variant angina).
- It is also widely used in its extended-release formulations for the treatment of hypertension, either alone or in combination with other antihypertensive agents.
- The immediate-release formulations, while historically used for rapid blood pressure reduction, are generally discouraged for acute hypertensive crises due to their unpredictable and rapid onset of action, which can lead to profound hypotension and reflex tachycardia, potentially increasing the risk of adverse cardiovascular events.
- Therefore, for chronic conditions like hypertension and angina, the controlled-release or extended-release formulations are preferred to provide a smoother and more sustained therapeutic effect.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Nifedipine dosage is highly individualized and depends on the specific formulation (immediate-release or extended-release) and the patient's clinical response and tolerability. For extended-release formulations used in hypertension and angina, typical initial doses might range from 30 mg to 60 mg once daily, with careful titration up to a maximum of 90 mg to 120 mg daily, as needed. Immediate-release capsules are typically dosed multiple times a day (e.g., 10 mg to 30 mg three to four times daily), but their use is largely restricted to specific situations due to rapid onset and offset. Dosage adjustments may be necessary in patients with hepatic impairment, and the drug should be initiated at lower doses with cautious titration in such populations. Patients should always adhere to the prescribed dosing regimen and not discontinue the medication abruptly without consulting a healthcare professional. |
Safety & Warnings
Common Side Effects
- Common side effects associated with nifedipine are primarily related to its vasodilatory properties and include peripheral edema (swelling of the ankles and feet), headache, flushing (warmth, redness, or tingling under the skin), and dizziness.
- Other frequently reported adverse effects include fatigue, nausea, constipation, and palpitations.
- Less common but potentially serious side effects can include symptomatic hypotension, reflex tachycardia (especially with immediate-release formulations which can worsen angina in some patients), and gingival hyperplasia (overgrowth of gum tissue) with long-term use.
- Rare but severe adverse events may encompass hypersensitivity reactions, elevated liver enzymes, and transient visual disturbances.
- Patients should report any persistent or worsening side effects to their physician promptly.
Serious Warnings
- Black Box Warning: Nifedipine does not carry a formal FDA Black Box Warning. However, serious warnings and precautions are paramount to ensure safe and effective use. The most critical safety concern surrounds the use of immediate-release nifedipine formulations, particularly in the context of hypertensive emergencies or acute ischemic events. Rapid and profound reductions in blood pressure induced by immediate-release nifedipine can lead to reflex tachycardia, which may paradoxically increase myocardial oxygen demand and potentially precipitate or worsen myocardial ischemia, myocardial infarction, and cerebrovascular events. This risk has led to a strong recommendation against the use of immediate-release nifedipine for hypertensive crises. Healthcare professionals must exercise extreme caution, and alternative agents are generally preferred for acute blood pressure management. Patients with severe aortic stenosis or hypertrophic obstructive cardiomyopathy require careful assessment, as nifedipine-induced vasodilation could exacerbate their conditions.
- Nifedipine should be used with extreme caution in certain patient populations and clinical situations.
- Immediate-release nifedipine formulations have been associated with an increased risk of myocardial infarction and mortality when used for acute blood pressure reduction, particularly in hypertensive emergencies, due to rapid and profound drops in blood pressure and subsequent reflex tachycardia.
- Patients with severe aortic stenosis or hypertrophic cardiomyopathy may be at increased risk of cardiovascular events due to potential for significant afterload reduction.
- Peripheral edema is a common, dose-dependent side effect and should be monitored.
- Patients with pre-existing gastrointestinal narrowing, such as esophageal or intestinal strictures, should not use extended-release formulations as the non-deformable tablet matrix could potentially cause an obstruction.
- Concomitant consumption of grapefruit juice can significantly increase nifedipine plasma concentrations, leading to enhanced pharmacological effects and increased risk of adverse reactions, therefore, it should be avoided.
- Close monitoring is essential during initiation and dose titration.
How it Works (Mechanism of Action)
Nifedipine is a dihydropyridine calcium channel blocker that primarily acts by inhibiting the influx of extracellular calcium ions across the membranes of myocardial and vascular smooth muscle cells. By blocking voltage-gated L-type calcium channels, it reduces the availability of intracellular calcium necessary for muscle contraction. This action leads to a potent relaxation of smooth muscle in both peripheral and coronary arteries, resulting in significant peripheral vasodilation and coronary artery vasodilation. The peripheral vasodilation reduces systemic vascular resistance and, consequently, lowers blood pressure. Coronary vasodilation improves myocardial oxygen supply, which is beneficial in angina. Unlike non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem), nifedipine has minimal effects on cardiac contractility and conduction at therapeutic doses, primarily affecting vascular smooth muscle.